How we know
Every link on this study, and who decided it
The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.
6 links0 made here, not in the record15 judgments2 judges (our rules as one)1 record change seen4 read an older version
Claude Opus 5.5Our rulesRecord updated on ClinicalTrials.govReplaced, or read an older version
Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102
From the registry record2 judgments on this linkRole in the study, from the registry to what was judged
RegistryEntry “TQB2102 for injection”the record gives no role
→judged=agreesHow the 2 judgments split100%of judgments with a known value say Tested
Tested · 2
All judgments on this study
| When | Link | Judge | Decision | State |
|---|---|---|---|---|
| Nov 2 | Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Claude Opus 5.5 | Tested | Read an older version |
| Nov 2 | Trastuzumab | Claude Opus 5.5 | Comparator | Read an older version |
| Nov 2 | Pertuzumab | Claude Opus 5.5 | Comparator | Replaced |
| Nov 2 | Docetaxel | Claude Opus 5.5 | Comparator | Read an older version |
| Nov 2 | Carboplatin | Claude Opus 5.5 | Comparator | Read an older version |
| Nov 2 | The record itself | ClinicalTrials.gov record | Version of 2026-11-02 | Record change |
| Nov 2 | The record itself | Our nightly check | Reading set aside | Current |
| Nov 3 | The record itself | Our nightly check | Read again | Current |
| Nov 3 | Pertuzumab | Claude Opus 5.5 | Comparator | Current |
| Nov 14 | Breast Neoplasms | Our condition-kind rule | Finest filed term | Current |
| Nov 18 | Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Our role rule | Tested | Current |
| Nov 18 | Trastuzumab | Our role rule | Comparator | Current |
| Nov 18 | Pertuzumab | Our role rule | Comparator | Agrees |
| Nov 18 | Docetaxel | Our role rule | Comparator | Current |
| Nov 18 | Carboplatin | Our role rule | Comparator | Current |
| As of now | Breast Neoplasms | Our main-condition rule (R9) | Main condition | Current |